|
KMID : 0545120070170040611
|
|
Journal of Microbiology and Biotechnology
2007 Volume.17 No. 4 p.611 ~ p.615
|
|
|
Immunogenicity and Safety of Vi Capsular Polysaccharide Typhoid Vaccine in Healthy Persons in Korea
|
|
Lim Sang-Min
Jung Hahn-Sun
Kim Min-Ja
Park Dae-Won
Kim Woo-Joo
Cheong Hee-Jin
Park Seung-Chul
Lee Kwang-Chul
Shin Young-Kyoo
Tan Hyun-Kwang
Kim Sang-Lin
Sohn Jang-Wook
|
|
|
Abstract
|
|
|
|
The purpose of this study was to evaluate the immunogenicity and safety of Salmonella Typhi Vi capsular polysaccharide vaccine (Vi vaccine) in Korea. The immunogenicity of a single dose of Vi vaccine was evaluated in 157 subjects (75 children and 82 adults) before and at 1, 6, and 12 months after vaccination. Immunogenicity was measured with a passive hemagglutination assay (PHA), quantified as geometric mean titers (GMTs) and seroconversion rates. The safety of the vaccine was investigated by determining adverse reactions occurring within 4 h, 3 days, and 1 month after injection. The seroconversion rate for children and adults 1 month after vaccination was 96.92% and 89.02%, respectively. In the case of children, the GMTs of Vi antibodies before vaccination were 5.87±1.34 and 142.59±2.39 at one month after vaccination. For adults, the GMTs before and one month after vaccination were 5.58±1.28 and 58.56±3.67, respectively. Vi antibodies persisted for as long as 6 and 12 months after vaccination. All adverse reactions in adults and children were minor and did not require treatment. The Vi CPS vaccine was safe and immunogenic in adults and children older than 5 years.
|
|
|
KEYWORD
|
|
|
Vi capsular polysaccharide typhoid vaccine, immunogenicity, safety
|
|
|
FullTexts / Linksout information
|
|
|
|
|
|
Listed journal information
|
|
  
|